

KWAR 23

| | |
|-----------|---|
| Cat. No.: | HY-P99175 |
| CAS No.: | 2243227-60-1 |
| Target: | Others |
| Pathway: | Others |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | | | | | | | | | | |
|--------------------|---|--|---------------|--|----------------|-------------|------------------|--|---------|---|
| Description | <p>KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research^[1].</p> | | | | | | | | | |
| In Vitro | <p>KWAR 23 (0-1 μM; 4 h) shows antitumor activity of human neutrophil and macrophage^[1]. KWAR 23 induces human macrophage-dependent phagocytosis in human tumor-derived cell lines^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human macrophages and lymphoma cells</td> </tr> <tr> <td>Concentration:</td> <td>0-1 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>4 h</td> </tr> <tr> <td>Result:</td> <td>Showed human macrophages and neutrophils killing tumor cells following treatment with KWAR23.</td> </tr> </table> | | Cell Line: | Human macrophages and lymphoma cells | Concentration: | 0-1 μ M | Incubation Time: | 4 h | Result: | Showed human macrophages and neutrophils killing tumor cells following treatment with KWAR23. |
| Cell Line: | Human macrophages and lymphoma cells | | | | | | | | | |
| Concentration: | 0-1 μ M | | | | | | | | | |
| Incubation Time: | 4 h | | | | | | | | | |
| Result: | Showed human macrophages and neutrophils killing tumor cells following treatment with KWAR23. | | | | | | | | | |
| In Vivo | <p>KWAR23 (intraperitoneal injection; 10 mg/kg; every other day; 21 d) exhibits effective antitumor activity in a human SIRPA knockin mouse model^[1]. KWAR23 enhances neutrophil and macrophage antitumor activity in SRG Mice^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>SIRPA knock-in mouse model injected with Burkitt's lymphoma cells^[1]</td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; 10 mg/kg; every other day; 21 d</td> </tr> <tr> <td>Result:</td> <td>Led to strong inhibition of tumor growth when combined with Rituximab.</td> </tr> </table> | | Animal Model: | SIRPA knock-in mouse model injected with Burkitt's lymphoma cells ^[1] | Dosage: | 10 mg/kg | Administration: | Intraperitoneal injection; 10 mg/kg; every other day; 21 d | Result: | Led to strong inhibition of tumor growth when combined with Rituximab. |
| Animal Model: | SIRPA knock-in mouse model injected with Burkitt's lymphoma cells ^[1] | | | | | | | | | |
| Dosage: | 10 mg/kg | | | | | | | | | |
| Administration: | Intraperitoneal injection; 10 mg/kg; every other day; 21 d | | | | | | | | | |
| Result: | Led to strong inhibition of tumor growth when combined with Rituximab. | | | | | | | | | |

REFERENCES

[1]. Ring NG, et al. Anti-SIRP α antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA